Citations

Clear

9383 citation(s) found for "Thomas, PS".

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry , Costello, Caitlin , D’Angelo, Christopher R. , Derman, Benjamin A. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Valent, Jason , Varshavsky‐Yanovsky, Asya, Kovách, E, Holmberg, Leona , Anderson, Larry D. , Anderson, Larry D , Derman, Benjamin A , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Devarakonda, Srinivas , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovach, Emily, Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 132-140

10.6004/jnccn.2025.0023 | PMID 40340857 Get It

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy
Stopeck, Alison , Abu‐Khalaf, Maysa , Chmielowski, Bartosz , Rao, Ruta , Xie, Bin , Dudek, Arkadiusz Z. , Mina, Lida A. , O’Shaughnessy, Joyce , Mattson, Paulette, Gargano, Michele , Cox, Joanna, Osterwalder, B , Drees, Jeremy, Chan, Anissa , Qiu, Xiaohong, Ottoson, Nadine, Bose, Nandita , Uhlik, Mark, Graff, J. J., Chmielowski, Bartosz , Rao, Ruta , Dudek, Arkadiusz Z , Gargano, Michele , Osterwalder, Bruno , Borges, Virginia F. , Xie, Bin, Chisamore, Michael Jon , Harrison, Ben, Ottoson, Nadine, Iglesias, José

Mayo Clinic

The Journal of Immunology | May 8, 2025 | Volume: 214 | Issue: 7 | Pages: 1529-1538

10.1093/jimmun/vkaf079 | PMID 40338159 Get It

Abstract The Phase 2 IMPRIME 1 study evaluated the combination of the pathogen-associated molecular pattern (PAMP) Imprime with the immune checkpoint inhibitor (ICI) pembrolizumab as second or later line of treatment (2 L+) for patients with metastatic triple-negative breast cancer (mTNBC). Eligible patients with mTNBC received weekly Imprime (4 mg/kg) intravenously in combination with pembrolizumab (200 mg every 3 weeks). Primary endpoints were overall response rate (ORR) and safety. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression free survival (PFS), and overall survival (OS). Exploratory endpoints included correlations between immune cell activation markers in tumor tissues and blood and response to therapy. Of the 42 evaluable patients, six had a response (one complete, five partial), with an ORR of 14.3% by RECIST v1.1. Median PFS was 2.7 months, median OS was 16.4 months, and DCR was 54.8%, with responders achieving a median DoR of 15.2 months. Therapy was generally well tolerated and resulted in an increase of immune activation markers, with higher levels of activation in peripheral blood associated with response and improved survival. The combination of Imprime and pembrolizumab was safe and demonstrated immune activation in tumor tissues and peripheral blood in patients with TNBC. Improved response rates were observed compared to historical studies of ICI monotherapy in similar patient populations. Study number (ClinicalTrials.gov trial registration): NCT02981303.
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Kleinberg, Lawrence , Lacy, Jill , Lee, Byrne , Licciardi, Frank, Ly, Quan P. , Matsukuma, Karen , McNamara, Michael, Mukherjee, Sarbajit , Mulcahy, Mary F. , Reddi, Deepti , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Uboha, Nataliya V. , Willett, Christopher G. , Yoon, Harry H. , McMillian, Nicole R., Stein, MaryElizabeth , Gupta, Garima , Ajani, Jaffer A , Bentrem, David J. , Gibson, Michael K. , Gupta, Garima , Kim, Sunnie S. Y. , Klempner, Samuel J. , Lloyd, Shane , Merkow, Ryan P. , Perry, Kyle A. , Pimiento, José M. , Reddi, Deepti , Wainberg, Zev A. , Woo, Yanghee

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 169-191

10.6004/jnccn.2025.0022 | PMID 40341199 Get It

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
Self-Motion Perception Influences Postural Sway More than Environmental Motion Perception
Critelli, Kyle, Carpenter, Mark G. , Anson, Eric R , Chen, Edward , Staab, Jeffrey P. , Crane, Benjamin Thomas

Mayo Clinic

No container title available | May 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.02.651511 | PMID 40655001 Get It

Abstract Motion of the visual field can alter postural sway and cause illusions of self-motion. The relative perceptual sensitivity of self-motion versus visual field motion induced by virtual reality (VR) stimulation and whether observable sway differs based on perceptual task is unknown. Methods to quantify sway perception while concurrently measuring sway do not exist. We measured head sway and motion perception (self or world) in healthy adults who stood with feet together wearing a VR headset while experiencing adaptive staircases of virtual sinusoidal pitch rotation about the ankle axis. In separate conditions of randomly ordered blocks, subjects were asked to indicate (yes/no) if the room moved (regardless of perceived postural sway) or if their postural sway increased (regardless of perceived room motion). Head sway area was measured by tracking movement of the VR headset. Yes/No responses were fit with psychometric curves to determine points of subjective equality (PSEs) for room motion and postural sway. PSEs were compared between conditions. Effects of motion perception (binary responses) on head sway area before, during, and after visual stimulation were examined. The mean PSE for room motion (0.42 degrees) was significantly lower than for postural sway (2.02 degrees) [t(1,18) = 4.4714, p = 0.00029]. Head sway area was significantly larger during (z = 11.53, p < 0.001) and after (z = 5.09, p < 0.001) visual stimulation only when participants perceived increased postural sway. Nearly 5-fold greater amplitudes of oscillating VR visual stimuli were required to induce perceptions of altered self-versus visual field motion. Observed head sway during visual motion was only linked to perceptual responses when participants focused internally on self-motion, not externally on room motion.
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction
Cecchini, Reena S. , Santos, Jennifer De Los , Umphrey, Heidi , Julian, Thomas B. , Mamounas, Eleftherios P. , White, Julia , Balanoff, Christa , Tan, Antoinette R. , Weber, Joseph J., Edmonson, David , Brown‐Glaberman, Ursa, Diego, Emilia J. , Teshome, Mediget , Matsen, Cindy , Seaward, Samantha A. , Wapnir, Irene , Wagner, Jamie L., Tjoe, Judy A., Thompson, Alastair M., Seaward, Samantha A , Basik, Mark , Mamounas, Eleftherios P. , Lucas, Peter C. , Wolmark, Norman

Mayo Clinic

JAMA Surgery | May 7, 2025 | Volume: 160 | Issue: 7 | Pages: 723

10.1001/jamasurg.2025.1072 | PMID 40332918 Get It

Importance Use of modern neoadjuvant chemotherapy (NAC) regimens has markedly increased rates of pathologic complete response (pCR) in breast cancer, raising the question of whether surgical removal of the primary tumor is required for patients with pCR. For surgery to be omitted, one must be able to accurately predict pCR before surgery. Objective To investigate if adding post-NAC core needle biopsy of the tumor bed to trimodality imaging in patients who have clinical complete response (cCR) will predict pCR (resolution of both invasive disease and ductal carcinoma in situ) in 90% or more cases. Design, Setting, and Participants This was a phase 2, prospective, nonrandomized clinical trial. Patients were enrolled from August 2017 to June 2019. This is the final analysis, which was completed in December 2023. The setting included academic and community hospital center members of NRG (ie, the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group) in the US and Canada. Patients with operable (T1-T3, stage I-III) invasive ductal carcinoma who completed NAC and achieved cCR and radiological complete response (rCR) or near rCR by mammography (mass ≤1 cm and no malignant microcalcifications), ultrasound (mass ≤2 cm), and magnetic resonance imaging (no mass with rapid rise or washout kinetics). Interventions Patients underwent marker-directed stereotactic multiple-core needle biopsy of the tumor bed with marker placement before breast-conservation surgery. Main Outcomes and Measures End points were negative predictive value (NPV) and sensitivity of the biopsy. Results A total of 105 patients were enrolled with 101 evaluable (mean [SD] age, 52.8 [10.5] years); 77 patients (76.2%) were younger than 60 years, and all breast cancer subtypes were represented with 32 (31.7%) triple-negative breast cancer, 21 (20.8%) hormone receptor–positive/epidermal growth factor receptor 2 ( ERBB2 ; formerly HER2 )–negative ( ERBB2 −) breast cancer, and 46 (45.5%) ERBB2 -positive ( ERBB2 +) breast cancer. In 101 evaluable patients, 36 had residual disease at surgery (pCR = 64%). With imaging criteria, NPV of the biopsy was 78.3% (95% CI, 67.9%-86.6%), and the sensitivity of the biopsy was 50% (95% CI, 32.9%-67.1%). In an exploratory subset analysis, the NPV in patients with ERBB2 + breast cancer was 90% (95% CI, 76.3%-97.2%). On retrospective central review, 62 of 101 enrolled patients met imaging eligibility criteria. In this exploratory post hoc analysis, NPV in these patients was 86.8% (95% CI, 74.7%-94.5%). Conclusions and Relevance These findings do not support breast conservation treatment without surgery based on the study criteria for cCR and rCR/near rCR by trimodality imaging and negative tumor-bed biopsy. Strict adherence to imaging criteria may be required to achieve acceptable predictive values. TRIAL Registration ClinicalTrials.gov Identifier: NCT03188393
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Rovin, Brad H. , Alvarado, Anthony, Aranow, Cynthia , Broder, Anna , Chowdhary, Vaidehi , Contreras, Gabriel, Felix, Christele, Gibson, Keisha L. , Hersh, Aimee O. , Kalunian, Kenneth , Rollins, Brandi , Smith, Benjamin J. , Thomas, Asha , Timlin, Homa , Ward, Michael D. , Cunha, Joanne S., DeQuattro, Kimberly , Figueroa‐Parra, Gabriel , Greco, Jessica , Cuéllar‐Gutiérrez, María C. , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kelly V. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Ferucci, Elizabeth D , Hersh, Aimee O , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Kirou, Kyriakos A , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Rovin, Brad H , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Barnado, April , Contreras, Gabriel, Ferucci, Elizabeth D. , Izmirly, Peter , Kamen, Diane L. , Rollins, Brandi, Thomas, Asha, Azzam, Muayad , Bartels, Christie M. , Fava, Andrea , Garg, Shivani , Kawtharany, Hassan , Kirou, Kyriakos A. , Mustafa, Reem A

Mayo Clinic

Arthritis & Rheumatology | May 7, 2025 | Volume: 77 | Issue: 9 | Pages: 1115-1135

10.1002/art.43212 | PMID 40331662 Get It

ObjectiveThe objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.MethodsThe Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.ResultsWe present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.ConclusionThis guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.
Echocardiographic nomograms in children living at high altitude according to sex
Mekonnen, Demeke, Ren, Ben , Mercado, Jorge, Kurmann, Reto , Zürcher, Fabian, Krähenmann, Peter, Llerena, Nassip , Torres, Pedro Iturralde , Pilgrim, Thomas , Spitzer, Ernest , Ren, Claire B , Pilgrim, Thomas , Spitzer, Ernest , Garcia-Ruiz, Victoria , Torres, Pedro

Mayo Clinic

European Heart Journal - Imaging Methods and Practice | May 5, 2025 | Volume: 3 | Issue: 1 | Pages: No page available

10.1093/ehjimp/qyaf053 | PMID 40416836 Get It

Abstract Aims This study aimed to establish 2D and M-mode echocardiographic reference values for cardiac chambers, outflow tracts, and great vessels for school children living at high altitudes, differentiated between males and females. Methods and results This post hoc analysis included children with normal echocardiography from a cluster randomized cross-sectional survey of rheumatic heart disease among school children in Peru. The echocardiograms were acquired with a portable machine and the images were analysed centrally with a standardized methodology. Body surface area (BSA) was used as an independent variable to predict the mean values of echocardiographic measurements for both male and female groups. Reference values are presented on z-scores and nomograms based on sex. Propensity score matching was used to compare sexes. A total of 985 students aged 5–16 years were included. The Haycock formula provided the best fit and was used when presenting data as predicted values for a given BSA. The z-score and nomograms for all essential parameters of cardiac chambers, great vessels, and functional surrogates are presented based on sex. The majority of the parameters were significantly different per sex after propensity score matching. Conclusion Normal reference values and nomograms of cardiac chambers, outflow tracts, and great arteries in healthy school children living at high altitudes based on sex were reported. These data partly addressed the existing gaps in paediatric echocardiographic nomograms.
A Quarterly Multidisciplinary Craniofacial Operative Team Conference to Improve Surgical Outcomes and Adherence to Clinical Pathways: Does it Work?
Grove, Austin M. , Kirsch, Hannah M., Hanley, Seth P., Bristol, Ruth E., Kurnik, Nicole M. , Singh, Davinder J. , Singh, Davinder J , Grove, Austin , Sitzman, Thomas J.

Mayo Clinic

Journal of Craniofacial Surgery | May 5, 2025 | Volume: 36 | Issue: 7 | Pages: 2306-2310

10.1097/scs.0000000000011468 | PMID 40323582 Get It

Craniofacial surgery requires a multidisciplinary care approach in the perioperative period. In an effort to guide clinical decision making and standardize care, many institutions have implemented craniofacial surgical pathways, describing numerous variables to monitor and specific actions that must be completed by each involved discipline in the perioperative period. Adherence to these pathways can be challenging given the complexity of the protocol and the multiple disciplines involved. In an effort to improve adherence to our institution’s perioperative pathway, the authors implemented a quarterly, multidisciplinary craniofacial operative team meeting to review the pathway and improve the quality of care. The authors report results from a retrospective review of craniosynostosis suturectomy operations at a single site in the 2 years before and 2 years after the start of our team meeting to review perioperative care. A total of 141 operations were included (70 before the meeting and 71 after). Perioperative outcomes and adherence to our surgical pathway were compared. Following the start of our team meetings, there was a significant decrease in the time under anesthesia, patients requiring blood transfusion, and total hospital length of stay ( P <0.05). There was also improved adherence to the craniofacial pathway, with significantly more operations applying peripheral nerve blocks to all locations specified in our pathway with the proper drug contents ( P <0.05). Our findings suggest that craniofacial operative team meetings with a goal of reviewing the surgical pathway and discussing improvements in care plans with all involved providers can significantly improve adherence to operative pathways and surgical outcomes.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update
Garje, Rohan , Riaz, Irbaz Bin , Naqvi, Syed Arsalan Ahmed , Rumble, R. Bryan , Taplin, Mary‐Ellen , Kungel, Terry M. , Herchenhorn, Daniel , Zhang, Tian , Beckermann, Kathryn E. , Vapiwala, Neha , Celano, Paul , Hotte, Sebastién J. , Borno, Hala T. , Bryce, Alan H. , Wulff‐Burchfield, Elizabeth , He, Huan, Williams, J.E. Caerwyn , Hotte, Sebastien J , Basu, Arnab , Borno, Hala , Bryce, Alan H , Wulff-Burchfield, Elizabeth , Bodei, Lisa , Hamilton, Robert J , Emamekhoo, Hamid , Hope, Thomas A , Murad, M Hassan , Liu, Hongfang , Williams, James E , Parikh, Rahul A , Garje, Rohan , Herchenhorn, Daniel , He, Huan , Riaz, Irbaz B , Beckermann, Katy , Rumble, R Bryan , Carducci, Michael A. , Basu, Arnab , Wang, Peng , Bodei, Lisa , Loblaw, Andrew , Emamekhoo, Hamid , Hope, Thomas A. , Murad, M. Hassan , Liu, Hongfang

Mayo Clinic

Journal of Clinical Oncology | May 2, 2025 | Volume: 43 | Issue: 20 | Pages: 2311-2334

10.1200/jco-25-00007 | PMID 40315400 Get It

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more . PURPOSE To provide evidence-based recommendations for patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS An Expert Panel including patient representation completed a systematic review of the evidence and made recommendations. RESULTS Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic agents (docetaxel, cabazitaxel), radiopharmaceuticals (radium 223, 177 Lu-prostate-specific membrane antigen [PSMA]-617), and sipuleucel-T have demonstrated an overall survival (OS) benefit for patients with mCRPC. For patients with BRCA1 / 2 alterations who did not receive prior ARPI, the combination of PARPi and ARPI (talazoparib + enzalutamide, olaparib and/or niraparib + abiraterone) has shown clinical benefit. For patients with BRCA1 / 2 alterations who received prior ARPI or ARPI followed by docetaxel, olaparib showed OS benefit. In select patients with microsatellite instability-high/mismatch repair-deficient, pembrolizumab showed clinical efficacy. RECOMMENDATIONS Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early adoption of somatic genetic testing and palliative care is recommended. Patients with mCRPC and bony metastases should receive a bone-protective agent. The panel recommends the combination of ARPI with PARPi in patients with BRCA1 / 2 alterations who did not receive prior ARPI. For patients who received prior ARPI, the panel recommends docetaxel chemotherapy. The panel recommends 177 Lu-PSMA-617 or cabazitaxel chemotherapy for patients who receive prior ARPI and docetaxel chemotherapy. For patients with BRCA1 / 2 alterations who received prior ARPI, the panel recommends PARPi monotherapy. Radium 223 is recommended for patients with symptomatic bone–only disease. Evidence for optimal sequencing for mCRPC regimens is lacking. Additional information is available at www.asco.org/genitourinary-cancer-guidelines .